Standard BioTools (NASDAQ:LAB – Get Rating) is one of 42 public companies in the “Analytical Instruments” industry, but how does it stack up against its competitors? We will compare Standard BioTools to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability.
This is a summary of recent reviews of Standard BioTools and its rivals, as reported by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Standard biological tools||0||0||0||0||N / A|
|BioTools Standard Competitors||149||963||1634||51||2.57|
As a group, the “Analytical Instruments” companies have an upside potential of 39.94%. Since Standard BioTools’ rivals have a higher likely upside, analysts clearly believe that Standard BioTools has less favorable growth aspects than its rivals.
Institutional and insider ownership
62.0% of the shares of all “Analytical Instruments” companies are held by institutional investors. 2.9% of Standard BioTools shares are held by insiders. By comparison, 13.4% of the shares of all Analytical Instruments companies are held by insiders. Strong institutional ownership indicates that hedge funds, large fund managers, and endowments believe a stock will outperform the market over the long term.
This table compares the net margins, return on equity and return on assets of Standard BioTools and its competitors.
|Net margins||Return on equity||return on assets|
|Standard biological tools||-93.89%||-63.43%||-18.45%|
|BioTools Standard Competitors||-250.85%||6.38%||-11.11%|
Valuation and benefits
This chart compares the gross revenue, earnings per share (EPS), and valuation of Standard BioTools and its rivals.
|Gross revenue||Net revenue||Price/earnings ratio|
|Standard biological tools||$130.58 million||-$59.24 million||-1.05|
|BioTools Standard Competitors||$1.16 billion||$344.59 million||-30.50|
Competitors of Standard BioTools have higher revenues and profits than Standard BioTools. Standard BioTools trades at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Standard BioTools has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Standard BioTools’ competitors have a beta of 1.21, suggesting that their stock price average is 21% more volatile than the S&P 500. .
Rivals Standard BioTools beat Standard BioTools on 7 of the 10 factors compared.
Standard BioTools Company Profile (Get a rating)
Standard BioTools Inc. designs, manufactures and markets instruments, consumables, reagents and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers and flow conductors; and tests and reagents, including Maxpar reagents, Maxpar direct immune profiling tests, Maxpar on-demand reagents and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments including the Biomark HD system and the EP1 system. In addition, it offers Integrated Fluid Circuits (IFCs), such as Library Preparation IFCs, Juno Genotyping IFCs, Dynamic Array IFCs, Digital Array IFCs, and Flex Six IFCs; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays , access matrix target-specific primers and targeted assays sequencing preparation primers and targeted DNA library analyzes Seq. Additionally, the company offers single-cell microfluidics including C1 systems; preparatory analytical instruments, which include C1 CFIs; and software solutions. It sells its products to university research institutes; translational research and medicine centres; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has licensing agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive daily news and reviews for Standard BioTools – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Standard BioTools and related companies with MarketBeat.com’s FREE daily newsletter.